CD258 (LIGHT) Antibody, anti-human, REAfinity™
Synonyms: TNFSF14, HVEML, LIGHT, LTg, TR2
RECOMBINANT
Bioz Star93/100 Bioz rating
1 Citation
Clone:
REA244 | 115520
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD258 (LIGHT) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
FITC
PE
PE-Vio 770
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-132-737, 130-132-766
Description:
Human peripheral blood mononuclear cells (PBMCs), either left unstimulated (left image) or stimulated with 1 µg/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/mL ionomycin for 48 hours, were stained with CD258 (LIGHT) antibodies as well as with CD8 antibodies. Cells were then analyzed by flow cytometry using the MACSQuant® Analyzer.The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
Specifications for CD258 (LIGHT) Antibody, anti-human, REAfinity™
Overview

Clone REA244 recognizes the CD258 antigen, a type II transmembrane protein, which is also known as tumor necrosis factor ligand superfamily member 14 (TNFSF14), herpes virus entry mediator ligand (HVEML), or LIGHT, the acronym for “homologous to lymphotoxins, inducible expression, competes with HSV glycoprotein D for HVEM, a receptor expressed on T lymphocytes”. CD258 is expressed by activated T cells, NK cells, monocytes, granulocytes, and immature dendritic cells. The ligands of CD258 are HVEM, lymphotoxin β receptor, and decoy receptor DcR3/TR6. CD258 has been shown to stimulate the proliferation of T cells, and trigger apoptosis of various tumor cells. CD258 is also reported to prevent tumor necrosis factor alpha–mediated apoptosis in primary hepatocytes. Its blockade or targeted disruption can alleviate alloresponses, graft rejection, or graft-versus-host disease.

Additional information: Clone REA244 displays negligible binding to Fc receptors.

Alternative names

TNFSF14, HVEML, LIGHT, LTg, TR2

Detailed product information

Technical specifications

Clone
REA244
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD258 (LIGHT)
Molecular mass of antigen [kDa]
26
Distribution of antigen
dendritic cells, granulocytes, monocytes, NK cells, T cells
Entrez Gene ID
RRID
AB_2656719, AB_2656712, AB_2656720, AB_2656713, AB_2656711, AB_2904875, AB_2904876, AB_2656714

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD258 (LIGHT) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?